“Boston Biotech Week and RESI underscore RoosterBio’s mission to radically change how stem cells are used in product development, process development, and clinical manufacturing. It’s one small step, but it’s how we change the world.” -Dr. Jon A. Rowley, Founder and Chief Product Officer, RoosterBio
FREDERICK, Md. (PRWEB) August 30, 2018
When it comes to regenerative medicine, science fiction and science fact are moving closer together every day. Beginning Sept 3, 2018, Biotech Week Boston is a chance for innovators and industry leaders to find inspiration in each other, pushing boundaries ever further. RoosterBio Inc., the leading supplier of human mesenchymal stem/stromal cell (hMSC)-specific Bioprocess Systems and manufacturing starting materials, is participating extensively. The company is garnering attention as a technology disruptor because its products significantly shorten the development timelines and clinical translation of hMSC-based therapeutic products.
Participants of the Cell & Gene Therapy Bioprocessing & Commercialization Conference and the Redefining Early Stage Investments (RESI) Conference will have numerous opportunities to explore RoosterBio’s roadmap to paradigm-shifting success. The Hynes Convention Center in Boston will house most of the Biotech Week events. RESI is located at the nearby Boston Marriott Copley Place.
RoosterBio’s leaders will take the stage at these dates and times:
Tuesday September 4, 2018 at the Cell & Gene Therapy event
- RoosterBio’s Sr. Project Manager Mithu Majumder, PhD, MBA, PMP will present a talk titled The Critical Role of cGMP Testing in Successful Commercialization of RoosterBio's CliniControl™ Products in a Pre-Conference Workshop on Raw Materials and is involved in a panel discussion at the end of the session.
- RoosterBio’s Founder & Chief Product Officer, Jon A. Rowley, PhD will present Why Stem Cell Manufacturing Matters: Production Platform and Media Strategy Drives Cell Product Economics in the Pre-Conference Workshop on Process Development and Manufacturing Scale Up for Engineered Tissues and will take part in a panel discussion at the end of the session.
Wednesday September 5, 2018 at the Cell & Gene Therapy event
- RoosterBio’s Process Engineer David Wang will be presenting a poster titled A Scalable Xeno-Free Microcarrier Suspension Bioreactor System for Regenerative Medicine Biomanufacturing of hMSCs in the technical poster session on Cell Culture and Upstream Processing.
Thursday September 6, 2018 at the Cell & Gene Therapy and RESI events
- RoosterBio’s Founder & Chief Product Officer, Jon A. Rowley, PhD will chair a Session on Process Automation and Closed Systems - Applications and Case Studies and will moderate an expert panel on the topic of Automation to close the session.
- RoosterBio’s Founder & Chief Product Officer, Jon A. Rowley, PhD will represent RoosterBio and participate in a panel discussion on fundraising in the session titled Tales from the Road at the RESI conference.
RoosterBio’s Founder, Jon A. Rowley, PhD, is a strong proponent of scientific collaboration and routinely mentors fellow biotech entrepreneurs. He says, “Boston Biotech Week and RESI underscore RoosterBio’s mission to radically change how stem cells are used in product development, process development, and clinical manufacturing. It’s one small step, but it’s how we change the world.”
For interviews and media relations, please contact Bryce Goodman.
About RoosterBio, Inc.:
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog “Democratizing Cell Technologies” (http://www.roosterbio.blogspot.com).